期刊
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
卷 19, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/ijerph191610189
关键词
post-COVID-19; intestinal microbiota; dysbiosis; antibiotics; sequelae
资金
- Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES) [88887.310463/2018-00, 88887.572 564/2020-00]
- Sao Paulo Research Foundation (FAPESP) [2022/0000-0]
- Brazilian National Council for Scientific and Technological Development (CNPq) [313190/2021-6, 313909/2020-2]
The dysbiosis of intestinal microbiota in COVID-19 patients, possibly induced by antibiotic use, may be associated with clinical manifestations in the post-COVID-19 period. Modulating the intestinal microbiota could be a therapeutic approach for recovering from acute COVID-19 and treating post-COVID-19 sequelae.
The intestinal microbiota plays an important role in the immune response against viral infections, modulating both innate and adaptive immune responses. The cytokine storm is associated with COVID-19 severity, and the patient's immune status is influenced by the intestinal microbiota in a gut-lung bidirectional interaction. In this study, we evaluate the intestinal microbiota of Brazilian patients in different post-COVID-19 periods, and correlate this with clinical data and the antibiotic therapy used during the acute phase. DNA extracted from stool samples was sequenced and total anti-SARS-CoV-2 antibodies and C-reactive protein were quantified. Compared with controls, there were significant differences in the microbiota diversity in post-COVID-19 patients, suggesting an intestinal dysbiosis even several months after acute disease resolution. Additionally, we detected some genera possibly associated with the post-COVID-19 dysbiosis, including Desulfovibrio, Haemophillus, Dialister, and Prevotella, in addition to decreased beneficial microbes, associated with antibiotic-induced dysbiosis, such as Bifidobacterium and Akkermansia. Therefore, our hypothesis is that dysbiosis and the indiscriminate use of antibiotics during the pandemic may be associated with post-COVID-19 clinical manifestations. In our study, 39% (n = 58) of patients reported symptoms, including fatigue, dyspnea, myalgia, alopecia, anxiety, memory loss, and depression. These data suggest that microbiota modulation may represent a target for recovery from acute COVID-19 and a therapeutic approach for post-COVID-19 sequelae.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据